Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO27 pembrolizumab in recurrent platinum-resistant PD-L1-positive ovarian, fallopian tube, and primary peritoneal cancer
2019-004365-41Phase 2Active
- Sponsor
- Policlinico Gemelli
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Policlinico Gemelli. Primary endpoint: Overall survival. Started May 2021; status: active.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2019-004365-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004365-41.